Summary
Several claims about indications and generic/price/patent details cannot be supported by the provided SAXENDA prescribing information sections (4, 5.1, 13.1, 17). Additionally, the weight-loss indication and diabetes indication are not supported/verified by the supplied label excerpts.
Category Scores
Accurate Statements
As of 2022, the patent for liraglutide has expired in some countries, allowing generic versions to be manufactured and sold.
Not addressed in provided label sections (4, 5.1, 13.1, 17).
Unsupported Statements
The cost of generic liraglutide can vary depending on location, pharmacy, and insurance coverage.
Cost, pricing factors, and generic availability are not discussed in the provided label sections.
The cost of generic liraglutide can range from $50 to $150 for a one-month supply of 6 mg injections.
Specific pricing ranges are not provided in the supplied label sections.
Liraglutide is a medication used to treat type 2 diabetes.
The provided label excerpts do not include indications/approved uses.
Liraglutide is used for weight loss.
The provided label excerpts do not include indications/approved uses.
The brand-name version of liraglutide (Saxenda) can cost around $1,000 to $1,500 per one-month supply.
Specific pricing is not provided in the supplied label sections.
Several factors can affect the cost of generic liraglutide, including pharmacy pricing, insurance coverage, and the number of doses prescribed.
Cost/pricing factors are not discussed in the supplied label sections.
Prices of generic liraglutide can vary depending on the medication strength.
Strength-based pricing is not discussed in the supplied label sections.
Higher strengths of liraglutide often cost more.
Strength-based pricing trends are not discussed in the supplied label sections.
In the United States, the patent for Saxenda is set to expire in 2026.
Patent expiration dates are not addressed in the provided label sections.
Contradictions
Important Omissions
Any label-supported contraindications/warnings, dosing, monitoring, or administration statements were not provided in support of claims about diabetes/weight loss, and the provided label excerpts do not verify those indications.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response includes unsupported claims about approved uses (type 2 diabetes and weight loss) and unrelated patent/cost information that is not present in the provided FDA label excerpts. Without label-supported indication information, the response could mislead about appropriateness of use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Key claims about indications (diabetes and weight loss) and all pricing/patent details are not supported by the provided prescribing information sections.
Suggested Improvement
Limit claims to information explicitly present in the supplied label excerpts (contraindications and thyroid C-cell tumor warning/counseling). Remove or qualify unsupported cost and patent statements, and provide indication/dosing text from the appropriate label sections if those claims must be evaluated.